Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (8): 942-948.doi: 10.12092/j.issn.1009-2501.2018.08.018

Previous Articles     Next Articles

Research progress of PD-1/PD-L1 pathway inhibitor in the immunotherapy of digestive system neoplasm

MENG Qiuhua, TIAN Jing, QIN Feizhang, QIN Yang, DONG Min   

  1. MENG Qiuhua, TIAN Jing, QIN Feizhang, QIN Yang, DONG Min
  • Received:2018-05-08 Revised:2018-07-03 Online:2018-08-26 Published:2018-08-28

Abstract:

Programmed cell death-1(PD-1) is an important co-inhibitory molecule expressing on T cell that has negative regulations on immune responses. When PD-1 bound to its ligand programmed cell death-ligand (PD-L1), PD-1/PD-L1 pathway can restrain the immune microenvironment, leading to the down-regulation of tumor-specific T cell activity, and contribute to tumor cells avoiding the immune surveillance and immune escape. PD-1/PD-L1 inhibitors may block its signaling pathway and enhance immune responses, thus inhibiting the growth of tumor cells. In this review, we discuss the therapeutics use of PD-1/PD-L1 monoclonal blocking antibodies in the immunotherapy of digestive system neoplasm.

Key words: PD-1/PD-L1, pathway inhibitors, neoplasms of digestive system, immunity therapy

CLC Number: